Novo Ventures is a private equity general partner firm headquartered in Hellerup, Denmark and has other offices in United States.
Kirsten Drejer is stepping down from its CEO position at PE-backed Symphogen and will become an independent member of the Board.
Tioma Therapeutics, which develops anti-CD47 antibodies that treat solid and hematologic cancers, has secured $86min Series A financing.
Galera Therapeutics, a clinical-stage biotech company developing new treatments for cancer patients, received an additional $5m in funding.
Read more news concerning Novo Ventures
A sampling of Novo Ventures portfolio companies:
View all of the investments in their portfolio
This firm also pursues other investment strategies:
Registration is fast, free and easy
Already a member?